Page last updated: 2024-10-27

formoterol fumarate and Parkinson Disease

formoterol fumarate has been researched along with Parkinson Disease in 1 studies

N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide : A phenylethanoloamine having 4-hydroxy and 3-formamido substituents on the phenyl ring and an N-(4-methoxyphenyl)propan-2-yl substituent.

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Weichert, D1
Stanek, M1
Hübner, H1
Gmeiner, P1

Other Studies

1 other study available for formoterol fumarate and Parkinson Disease

ArticleYear
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
    Bioorganic & medicinal chemistry, 2016, 06-15, Volume: 24, Issue:12

    Topics: Adrenergic beta-2 Receptor Agonists; Animals; Benzoxazines; CHO Cells; Cricetulus; Dopamine Agonists

2016